

Specific Distribution of *GJB2* Mutations in Kurdistan Province of Iran; Report of a Relatively Isolated Population

T. Bahrami¹, N. Jalilian², G. Karbasi³, M. R. Noori-Daloii^{*1}

¹ Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran

² Department of Clinical biochemistry, Faculty of medicine, Kermanshah University of Medical Sciences, Kermanshah, Islamic Republic of Iran

³ Kurdistan Welfare and rehabilitation Organization, Sanandaj, Kurdistan, Islamic Republic of Iran

Received: 19 June 2016 / Revised: 23 July 2016 / Accepted: 10 September 2016

Abstract

Hearing Loss (*HL*) represents high genetic heterogeneity with an incidence of almost 1 out of 500 newborns in most populations. Approximately half of the cases have a genetic basis that most of them are autosomal recessive non-syndromic (*ARNSHL*) with *DFNB1*-related defect in many worldwide populations. Given the heterogeneity of the trait together with the unique infrastructure of Iranian population, made it necessary to study other loci than *GJB2* in various ethnic groups in order to elucidate the genetic etiology of *HL* in Iran. The present study was designed to determine the contribution of four *DFNB* loci in Kurdistan Province, west Iran. In this connection, we performed *GJB2* analysis and homozygosity mapping using STR markers covering the *DFNB21*, *DFNB4* and *DFNB7/11* loci in 20 pedigrees with *ARNSHL*. *GJB2* mutations were the cause of *HL* in 20% of the patients. However, surprisingly, we only observed *35delG* and *IVS1+1G>A* mutation among the study population. We also did not find any family linked to *DFNB21*, *DFNB4* and *DFNB7/11*. Our results indicate the contribution of other loci in etiology of *HL* in Kurdistan that needs to be carefully investigated.

Keywords: *ARNSHL*; Iranian Kurdish people; *GJB2*; *DFNBs*.

Introduction

Hearing Loss (*HL*) is the most prevalent sensorineural disorder, affecting one out of every 500 newborns [1]. The majority (~70%) of cases are non-syndromic (non-syndromic hearing loss, *NSHL*) with the remaining 30% being associated with other clinical findings (syndromic hearing loss, *SHL*). The autosomal

recessive form of *NSHL* (*AIRNSHL*) accounts for over 80% of *NSHL* and is expected to be even more prevalent in families from consanguinity belt, including Iran [2, 3].

Identification of over 100 loci and 60 genes (www.hereditaryhearingloss.org), emphasizes the heterogenic nature of *ARNSHL*. In spite of this heterogeneity, *DFNB1* (*GJB2*) accounts for up to 50%

* Corresponding author: Tel: +982188953005; Fax: +982188953005; Email: nooridalooi@tums.ac.ir

of *ARNSHL* in many populations [4-7], with more than 300 variants described so far (www.hgmd.org). *GJB2* mutations also remain the major cause of *ARNSHL* in Iranian population but only approaching an average of ~16-18% of cases [8, 9]. On the other hand, analysis of *GJB2* mutations in different Iranian ethnic groups shows a remarkable difference. Therefore, it worth considering the molecular etiology of *ARNSHL* differs considerably among different Iranian ethnic groups.

SLC26A4 which encodes for the anion exchanger pendrin, is expressed in cells bordering the endolymph and spiral ganglion [10]. Mutations in the *SLC26A4* at DFNB4 locus cause both *ARNSHL* and Pendred syndrome, which is characterized by thyroid enlargement and *HL*. The *HL* phenotype is associated with abnormal inner ear development, identifiable by temporal bone imaging [10, 11]. To date, over 200 mutations have been reported in *SLC26A4* [MORL homepage. <http://www.medicine.uiowa.edu/pendredandbor>], making it the second cause of congenital *HL* after *GJB2*.

TMC1 gene encodes for transmembrane channel-like 1 protein which is a member of the subfamily A of transmembrane channel-like (*TMC*) gene family. *TMC1* mutations can cause both Autosomal recessive (DFNB7/11) and autosomal dominant (DFNA36) mode of hearing impairment [12, 13].

The *TECTA* gene encodes a-tectorin, which is one of the main noncollagenous parts of the tectorial membrane in the inner ear. Mutations in *TECTA* have been detected in both autosomal recessive and autosomal dominant *HL* (DFNB21 and DFNA8/12) [14, 15].

Iranian population is heterogenous with high rate of consanguineous marriage; however, few investigations have ever addressed the prevalence of DFNB loci other than DFNB1 in individual ethnic groups. This study investigates the contribution of *GJB2* and the prevalence of 3 frequent DFNB loci including DNB4, DFNB7/11 and DFNB21 in 20 Iranian *ARNSHL* families from Kurdistan province, west of Iran. These results give a preliminary overview of the molecular epidemiological characteristics of hereditary *HL* in this region and will provide data for better genetic diagnostics and counseling.

Materials and Methods

Subjects

Totally 20 large pedigrees compatible with autosomal recessive mode of inheritance, with at least 2 affected members were recruited. The families were referred to the Center for Genetic Counseling, Center of

the Welfare and Rehabilitation Organization, Sanandaj, Kurdistan province. All patients had bilateral prelingual hearing loss. The detailed history could not attribute *HL* to known environmental factors (such as CMV, trauma, aminoglycoside drugs). In addition, the possibility of *SHL* was excluded by detailed clinical examination. *HL* was confirmed with pure tone audiometry. After the Informed consent was obtained, peripheral blood samples were collected in 0.5 M EDTA containing tubes and genomic *DNA* was extracted using the salting out method [16]. Concentration and purity of *DNA* was measured (Nanodrop[®]TM1000-Thermo Scientific) and approximately 50 ng of the genomic *DNA* was used to genotype each sample. The study was approved by the Ethics committee of Tehran University o Medical Sciences (*TUMS*).

PCR-Sequencing and Screening of *GJB2* Exons

From each pedigree, one affected member was sequenced for exon1 and 2 of *GJB2* gene. Following primers were used for amplification of exon1 forward: 5'-CGACCACAGCCATCCCTGAACC-3' and reverse: 5'-GGACGTGTGTTGGTCCAGCC-3' which yielded a 684 bp band. Each *PCR* reaction condition was: : 0.8µl of each of the primers (10 PM), 7ul Mastermix (amplicon[®] Mastermix Contains MgCl₂, Taq *PCR* buffer, Taq *DNA* polymerase and *dNTPs*) and 1µl *DNA* (50ng/ul) adjusted to 25 µ by ddH₂O. *PCR* reactions were performed under the following condition: initial denaturation at 95°C for 2 minutes, followed by 33 cycles of denaturation at 95 °C for 30 s, 72 °C for 60 s, and final extension at 72 °C for 5 min.

Exon 2 was amplified based on the protocol described before. *PCR* products were run in 1/5% agarose gel electrophoresis. Bands were visualized by *EtBr* staining. Afterward, the *PCR*-amplified products were sequenced on an *ABI* 3130 automated sequencer (MacroGen[®], South Korea). Sequencing data were analyzed by chromas software. After identification of each variant, ensemble.org, dbSNP (<http://www.ncbi.nlm.nih.gov/snp>), 1000 genome databases (<http://browser.1000genome.org>) and HGMD (<http://www.hgmd.cf.ac.uk/ac/index.php>) were searched for previously known variants. Sequence variant numbering was based on the transcript ENST00000382848 for *GJB2*.

Genotyping and linkage analysis

At least, three informative short tandem repeat (*STR*) markers were analyzed for each locus. The *STR* markers were chosen based on their physical distance found at *NCBI* UniSTS and Map Viewer. Further markers were examined upon encountering an uninformative marker.

Table 1. List of the STR markers used in this study

| Locus (gene), Physical location(bp), Category& function | Marker | Physical position (bp) | PCR product range | Forward primer (5'→3') | Reverse primer (5'→3') |
|---|----------|---------------------------|-------------------------|-------------------------------|---------------------------|
| DFNB4(<i>SLC2 6A4</i>) 107301080..10 7358254) | D7S2420 | 106889928- 106890211 | 240-290 | CCTGTATGGAGGGCAAACCTA | AAATAATGACTGAGGCTCAAAACA |
| | D7S496 | 107154713- 107154849 | 129-141 | AACAACAGTCAACCCACAAT | GCTATAACCTCATAANAAACCAAAA |
| | D7S2459 | 107331501- 107331642 | 140-152 | AAGAAGTGCATTGAGACTCC | CCGCCCTTAGTAAAAACCC |
| | D7S2456 | 107683218- 107683460 | 238-252 | CTGGAAATTGACCTGAAACCTT | ACAGGGGTCTCTCACACATATTA |
| | D9S1837 | 75185129- 75185367 | 205-251 | CATGATGGTGGTCTCTGG | GGTGGGGCTCAAAGAGTAG |
| DFNB7/11(<i>T MC1</i>) 75136717..754 51267) | D9S1806 | 74201357- 74201620 | 216-266 | TTTAGGTGTCTCAGTACATGC | GGGAGCAACATTTTGACATT |
| | D9S1124 | 75224065- 75224327 | 252-276 | GGTGCCCACTACACTACT | TCTAATCCTTCCTTCCCTCG |
| | D9S1876 | 75232791- 75232938 | 132-152 | GATGTACCCAGAGAAGTCTCG | AGTGGTTACCATTTACCCAAG |
| | D9S301 | 73802720- 73802954 | 209-237 | AGTTTTCATAACACAAAAGAGA ACA | ACCTAAATGTTTCATCAAAAAGAGG |
| | D9S1822 | 74930323- 74930483 | 157-163 | AAGTTTGGCTTCTGTGTAAGG GTC | AATCCCCCAGGCTGAGTG |
| DFNB21(<i>TEC TA</i>) 120973375..12 1061515 | D9S1799 | 73366891- 73367055 | 139-178 | TGCCAACCTATTTAGCCC | TGCAGTTTCAATCCACATC |
| | D11S4107 | 121049124- 121049321 | 172-212 | TCATTCTACAAGACTAGCATTA CC | GCTTGATCATGGTGTATTATCTT |
| | D11S925 | 120828264- 120828438 | 172-199 | AGAACCAAGGTCGTAAGTCCTG | TTAGACCATTATGGGGGCAA |
| | D11S912 | 128624097- 128624205 | 101-123 | TCGTGAGANTACTGCTTTGG | TTTTGTCTAGCCATGATTGC |
| | D11S4151 | 126292160- 126292309 | 145-155 | GTCTTCCACCTTGGATATGGG TA | AATGGGCACCTCCACCTATTAGT |
| | D11S4089 | 120989673- 120989875 | 199-213 | ATTCCTAGTTCCTCATAAACA CTG | TAATCAAAGGCTGTAGTGAATTGG |
| | D11S4110 | 126971672- 126971780 | 93-107 | TGAGCCTCCAGTACCTACC | GTTTGTGGCAGAGCCCTAAG |

The used primer sequences are shown in Table 1.

STR markers were amplified by touch down PCR in an ABI thermal cycling 2720 (Applied Biosystems®, USA). PCR protocol and thermal cycling program are available upon request. Generally, PCR products were run on 8-12% PAGE at 15 mA for 4-6 h. Bands were visualized by silver staining. Alleles were assigned by visual assessment.

Two-point and multi-point parametric LOD scores were calculated by Superlink version 1.6 and Simwalk version 2.91 options of Easylinkage plus version 5.05 software [17]. After linkage analyses, haplotypes were reconstructed via Simwalk and were visualized by HaploPainter software version 029.5 [18].

Results

Screening of GJB2 Exons

Totally 20 large pedigrees including 46 affected and 60 healthy members were recruited, among which four

pedigrees showed *GJB2* mutations. Interestingly, three of four were compound heterozygous for *35delG* and splice site mutation of *IVS1+1G>A*, while one pedigree was homozygous for *35delG*. Pedigrees of the families positive for *GJB2* mutations and electropherograms of the mutations are depicted in Figure 1.

Genotyping STR Markers and Homozygosity Mapping

Families negative or heterozygote for DFNB1 mutations were screened for DFNB4, DFNB21 and DFNB7/11 loci by linkage analysis which no family showed to be linked to the mentioned loci.

Discussion

HL is the most common sensory defect with high clinical and genetic heterogeneity [19]. Up to now, over 100 loci have been mapped and about 60 genes identified for *ARNSHL* (<http://www.hereditaryhearingloss.org>). *GJB2* mutations in the DFNB1 locus




Figure 1. Pedigrees carried mutations at DFNB1 locus

are the main cause of *ARNSHL* in many ethnic groups, including Iran [20-22]. The prevalence of *HL* in Iran is 2-3 times greater than other populations [19] while *GJB2* mutations are responsible for 16.7% of *ARNSHL*

cases and this prevalence may vary among different ethnic groups.

Kurdistan population is located in the west part of Iran. Kurdish population of Iran is distributed among 4

different provinces including: Kurdistan, Kermanshah, Ilam and Azerbaijan while the population of Kurdistan province remains isolated by culture and religious approach. Findings of the current study showed that contribution of *GJB2* mutations in Kurdistan province of Iran is 20% that almost seem to be consistent with results of Mahdiah et al [23] also conducted on a Kurdish population. However, distribution of the variants is not exactly the same. In the current study, only 2 *GJB2* variants, including *35delG* and *IVS1+1G>A*, were observed while the other study found six variants including *35delG*, *R127H*, *del120E*, *R32H*, *IVS1+1G>A* and *R184P* [24]. It worth mentioning that study population of Mahdiah et al, mostly originate from Kermanshah province, which is less isolated in comparison to Kurdistan. This might be a possible explanation for the different mutational spectrum observed. This discrepancy may also arise due to differences in sample size which was larger in Mahdiah's et al.

In the Iranian Azeri patients, a frequency of 28% of mutant *GJB2* have been reported [25]. In HL population of Oman [26], Pakistan [27], Turkey [28], and Slovakia [29], contribution of *GJB2* gene mutations is 0%, 6.1%, 25%, and %45.6, respectively. In addition, some studies indicated 31.7% contribution of *GJB2* mutation in Turkey [30], in neighboring of Iranian Azeri Turkish residents.

Many allelic variations have been reported in *GJB2* (<http://www.hgmd.cf.ac.uk/ac/index.php>). Among different deafness-causing alleles, *35delG* mutation is the most common one. This frame shift mutation results in a truncated protein [19]. The frequency of this allele differs among different Iranian ethnic groups [21], for example, it is 71.6 % in Iranian Azeri Turkish population [31]. The present findings indicate a frequency of 62.5% and 37.5% for *35delG* and *IVS1+1G>A* among Kurdish people from Kurdistan province of Iran, respectively. *R127H*, *delE120*, *W24X*, *V27I+ E114G*, *R184P*, *-3170G4A* and *235delC* are the other most common mutations of *GJB2* in Iranian population [19] which were not observed in this study.

Here, we found no family linked to DFNB4, DFNB21 and DFNB7/11.

SLC26A4 gene, located on the DFNB4, 7q31[32], is considered to be the second leading cause of autosomal recessive HL in many populations [33]. Studies had reported frequencies of 10% and 4.8% for *SLC26A4* mutations in Iran [34, 35]. Interestingly, unlike the previous reports, no mutation was found in *SLC26A4* in our study population which consequently suggests that DFNB4 may not be a major locus in etiology of HL in Kurdistan Province of Iran.

TMCI at the DFNB7/11 locus on chromosome 9q31-21 (MIM 606706, GeneID 117531), encodes transmembrane channel-like 1 protein [38]. Mutations of this gene has been reported as a frequent cause of *ARNSHL* in several populations, including Pakistan, India and also Iran [39]. In a heterogeneous Iranian study population, 9.4% of *HL* families were linked to DFNB7/11 [40]. However another study failed to replicate this frequency and only a 2% contribution was observed [34]. Here, our results show that *TMCI* mutations are not an important cause for *ARNSHL* in Kurdistan population.

TECTA gene which has been mapped on chromosome 11q22-q24 (MIM 602574, GeneID 7007) [41, 42], encodes a protein of 2155 amino acids. *TECTA* mutations have been found in French, Belgian, Swedish and Austrian families [41]; in Iran, they are responsible for 4.1% of *ARNSHL* cases [43-45]. However, unlike previous studies, no mutation in *TECTA* was observed in our study population which suggests its minor contribution in etiology of HL Kurdish people from Iran.

Conclusion

In this study, we could find the genetic basis of *HL* in only four out of 20 pedigrees of the studied population, while the etiology in about 80% remains to be identified. *GJB2* mutations were the most common cause of *HL*, accounting for about 20% of the families. Regarding high frequency of *35delG* and *IVS1+1G>A*, it worth to detect carrier frequency of these two variants among normal population.

Other loci should also be investigated in order to clarify the molecular etiology of hearing loss in Kurdistan province. Our results highlight the heterogeneity of *HL* and provide clues for a different panel of DFNB loci involved in the etiology of hearing loss in the province.

Acknowledgments

The authors widely acknowledged the patients and their families for participation in this project. This work was supported by Tehran University of Medical Sciences (Grant number: 21676).

References

1. Mehl A. L. and Thomson V. The Colorado newborn hearing screening project, 1992-1999: on the threshold of effective population-based universal newborn hearing screening. *Peds.* **109**: 845-857 (2002).
2. Van C. G., Willems P. J. and Smith RJ. Nonsyndromic

- hearing impairment: unparalleled heterogeneity. *Am. J. Hum. Genet.* **60**: 758-764 (1997).
3. Banjara H., Mungutwar V., Swarnkar N. and Patra P. Detection of Connexion 26 GENE (GJB2) Mutations in Cases of Congenital Non Syndromic Deafness. *Indian. J. Otolaryngol. Head. Neck Surg.* **1-6**: 84-97 (2016).
 4. Denoyelle F., Marlin S., Weil D., Moatti L., Chauvin P., Garabedian EN. and Petit, C. Clinical features of the prevalent form of childhood deafness, DFNB1, due to a connexin-26 gene defect: implications for genetic counselling. *Lan.* **353**: 1298-1303 (1999).
 5. Kelsell DP., Dunlop J., Stevens HP., Lench NJ., Liang JN., Parry G. and Leigh M.. Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. *Nat.* **387**: 80-83 (1997).
 6. Kenneson A., Van Naarden Braun K. and Boyle C. GJB2 (connexin 26) variants and nonsyndromic sensorineural hearing loss: a HuGE review. *Genet. Med.* **4**: 258-274 (2002).
 7. Mielczarek M., Zakrzewska A. and Olszewski J. GJB2 sequencing in deaf and profound sensorineural hearing loss children. *Otolaryngol. Pol.* **70**: 21-29 (2016).
 8. Najmabadi H., Nishimura C., Kahrizi K., Riazalhosseini Y., Malekpour M., Daneshi A. and Bazazzadegan N. GJB2 mutations: passage through Iran. *Am. J. Med. Genet A.* **133A**: 132-137 (2005).
 9. Hashemzadeh Chaleshtori M., Farhud DD. and Patton MA. Familial and Sporadic GJB2-Related Deafness in Iran: Review of Gene Mutations. *Iranian. J. Publ. Health.* **36**: 1-14 (2007).
 10. Azaiez H., Yang T., Prasad S., Sorensen JL., Nishimura CJ., Kimberling WJ. and Smith J. Genotype-phenotype correlations for SLC26A4-related deafness. *Hum. Genet.* **122**: 451-457 (2007).
 11. Ma Y., Xiao Y., Bai X., Zhang F., Zhang D., Xu X. and Wang H. GJB2, SLC26A4, and mitochondrial DNA12S rRNA hot-spots in 156 subjects with non-syndromic hearing loss in Tengzhou, China. *Acta. Otolaryngol.* **1-6**: 432-443 (2016).
 12. Greinwald JH., Scott DA., Marietta JR., Carmi R., Manaligod J., Ramesh A. and Musy M. Construction of P1-Derived Artificial Chromosome and Yeast Artificial Chromosome Contigs Encompassing the DFNB7 andDFNB11 Region of Chromosome 9q13-21. *Genome. Res.* **7**: 879-886 (1997).
 13. Kurima K., Peters LM., Yang Y., Riazuddin S., Ahmed ZM., Naz S. and Ghosh M. Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function. *Nat. Genet.* **30**: 277-284 (2002).
 14. Verhoeven K., Van Laer L., Kirschhofer K., Legan PK., Hughes DC., Schatteman I. and Smith J. Mutations in the human α -tectorin gene cause autosomal dominant non-syndromic hearing impairment. *Nat. Genet.* **19**: 60-62 (1998).
 15. Balciuniene J., Dahl N., Jalonon P., Verhoeven K., Van Camp G., Borg E. and Jazin E. E. Alpha-tectorin involvement in hearing disabilities: one gene-two phenotypes. *Hum. Genet.* **105**: 211-216. (1999)
 16. Inge A. Simple salting - out method for genomic DNA extraction from whole blood. . *Tikrit. J. Pure. Sci.* **16**: 345-352 (2011).
 17. Hoffmann K. and Lindner TH. easyLINKAGE-Plus--automated linkage analyses using large-scale SNP data. *Bioinformatics.* **21**: 3565-3567 (2005).
 18. Thiele H and Nurnberg P. HaploPainter: a tool for drawing pedigrees with complex haplotypes. *Bioinformatics.* **21**: 1730-1732 (2005).
 19. Mahdih N., Rabbani B., Wiley S., Akbari MT. and Zeinali S. Genetic causes of nonsyndromic hearing loss in Iran in comparison with other populations. *J. Hum. Genet.* **55**: 639-648 (2010).
 20. Fattahi Z., Shearer AE., Babanejad M., Bazazzadegan N., Almadani SN., Nikzat N. and Azadeh B. Screening for MYO15A gene mutations in autosomal recessive nonsyndromic, GJB2 negative Iranian deaf population. *Am. J. Med. Genet A.* **158**:1857-1864 (2012).
 21. Najmabadi H., Nishimura C., Kahrizi K., Riazalhosseini Y., Malekpour M., Daneshi A. and Bazazzadegan N. GJB2 mutations: passage through Iran. *Am. J. Med. Genet A.* **133**: 132-137 (2005).
 22. Kelley P., Harris D., Comer B., Askew J., Fowler T., Smith S. and Kimberling W. J. Novel mutations in the connexin 26 gene (GJB2) that cause autosomal recessive (DFNB1) hearing loss. *Am. J. Hum. Genet.* **62**: 792-799 (1998).
 23. Rabbani B., Tekin M. and Mahdih N. The promise of whole-exome sequencing in medical genetics. *J. Hum. Genet.* **59**: 5-15 (2014).
 24. Mahdih N., Nishimura C., Ali-Madadi K., Riazalhosseini Y., Yazdan H., Arzhanghi S. and Najmabadi H. The frequency of GJB2 mutations and the (GJB6-D13S1830) deletion as a cause of autosomal recessive non-syndromic deafness in the Kurdish population. *Clin. Genet.* **65**: 506-508 (2004).
 25. Davarnia B., Babanejad M., Fattahi Z., Nikzat N., Bazazzadegan N., Pirzade A. and Kahrizi K. Spectrum of< i> GJB2</i>(Cx26) gene mutations in Iranian Azeri patients with nonsyndromic autosomal recessive hearing loss. *Int. J. Pediatr. Otorhinolaryngol.* **76**: 268-271 (2012).
 26. Simsek M., Al-Wardy N., Al-Khayat A., Shanmugakonar M., Al-Bulushi T., Al-Khabory M. and Al-Harthi S. Absence of deafness-associated connexin-26 (GJB2) gene mutations in the Omani population. *Hum. Mut.* **18**: 545-546 (2001).
 27. Santos R., Wajid M., Pham T., Hussan J., Ali G., Ahmad W. and Leal S. M.. Low prevalence of Connexin 26 (GJB2) variants in Pakistani families with autosomal recessive non-syndromic hearing impairment. *Clin. Genet.* **67**: 61-68 (2005).
 28. Kalay E., Caylan R., Kremer H., de Brouwer AP. and Karaguzel A. < i> GJB2</i> mutations in Turkish patients with ARNSHL: prevalence and two novel mutations. *Hear. Res.* **203**: 88-93 (2005).
 29. Minarik G., Ferakova E., Ficek A., Polakova H. and Kadasi L. GJB2 gene mutations in Slovak hearing-impaired patients of Caucasian origin: spectrum, frequencies and SNP analysis. *Clin. Genet.* **68**: 554-557 (2005).
 30. Uyguner O., Emiroglu M., Uzumcu A., Hafiz G., Ghanbari A., Baserer N. and Wollnik B. Frequencies of

- gap-and tight-junction mutations in Turkish families with autosomal-recessive non-syndromic hearing loss. *Clin. Genet.* **64**: 65-69 (2003).
31. Bonyadi M., Esmaceli M., Abhari M. and Lotfi A. Mutation analysis of familial GJB2-related deafness in Iranian Azeri Turkish patients. *Genet. Test. Mol. Biomarkers.* **13** (5):689-692 (2009).
 32. Everett L. A., Glaser B., Beck J. C., Idol J. R., Buchs A., Adawi F. and Green E. D. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). *Nat. Genet.* **17** : 411-422 (1997).
 33. Yazdanpanahi N., Tabatabaiefar MA., Bagheri N., Azadegan D. F., Farrokhi E. and Hashemzadeh Chaleshtori M. The role and spectrum of SLC26A4 mutations in Iranian patients with autosomal recessive hereditary deafness. *Int. J. Audiol.* **54**: 124-130 (2015).
 34. Babanejad M., Fattahi Z., Bazazzadegan N., Nishimura C., Meyer N., Nikzat N. and Smith R. J. A comprehensive study to determine heterogeneity of autosomal recessive nonsyndromic hearing loss in Iran. *Am. J. Med. Genet A.* **158**: 2485-2492 (2012).
 35. Kahrizi K., Mohseni M., Nishimura C., Bazazzadegan N., Fischer SM., Dehghani A. and Azizi F. Identification of SLC26A4 gene mutations in Iranian families with hereditary hearing impairment. *Eur. J. Pediatr.* **168**: 651-653 (2009).
 36. Park H., Shaukat S., Liu XZ., Hahn S., Naz S., Ghosh M. and Iazuddin S. Origins and frequencies of SLC26A4 (PDS) mutations in east and south Asians: global implications for the epidemiology of deafness. *J. Med. Genet.* **40**: 242-248 (2003).
 37. Coyle B., Reardon W., Herbrick J. A., Tsui L. C., Gausden E., Lee J. and Luxon L. Molecular analysis of the PDS gene in Pendred syndrome (sensorineural hearing loss and goitre). *Hum. Mol. Genet.* **7**: 1105-1112 (1998).
 38. Wu K., Wang H. and Wang Q. Advances in hereditary hearing loss caused by TMC1 mutations. *Zhonghua er bi yan hou tou jing wai ke za zhi= Chinese. J. Otorhinolaryngol. Head. Neck. Surg.* **51**: 224-229 (2016).
 39. Hildebrand M. S., Kahrizi K., Bromhead C. J., Shearer A. E., Webster J. A., Khodaei H. and Kimberling W. J. Mutations in TMC1 are a common cause of DFNB7/11 hearing loss in the Iranian population. *Ann. Otol. Rhinol. Laryngol.* **119**: 830-838 (2010).
 40. Noori-Dalooi M. Mutation Analysis of GJB2 and GJB6 Genes and the Genetic Linkage Analysis of Five Common DFNB Loci in the Iranian Families with Autosomal Recessive Non-Syndromic Hearing Loss. *J. Sci. I. R. Iran.* **21**: 105-112 (2010).
 41. Finsterer J. and Fellingner J. Nuclear and mitochondrial genes mutated in nonsyndromic impaired hearing. *Int. J. Pediatr. Otorhinolaryngol.* **69**: 621-647(2005).
 42. Kim AR., Chang M. Y., Koo J. W., Oh S. H. and Choi B. Y. Novel TECTA mutations identified in stable sensorineural hearing loss and their clinical implications. *Audiol. Neurotol.* **20**:17-25 (2014).
 43. Naz S., Alasti F., Mowjoodi A., Riazuddin S., Sanati M., Friedman T. and Wilcox E. R.. Distinctive audiometric profile associated with DFNB21 alleles of TECTA. *J. Med. Genet.* **40**: 360-363 (2003).
 44. Meyer NC., Alasti F., Nishimura C. J., Imanirad P., Kahrizi K., Riazalhosseini Y. and Smith R. J. Identification of three novel TECTA mutations in Iranian families with autosomal recessive nonsyndromic hearing impairment at the DFNB21 locus. *Am. J. Med. Genet A.* **143**: 1623-1629 (2007).
 45. Alasti F., Sanati M. H., Behrouzifard A. H., Sadeghi A., De Brouwer A. P., Kremer H. and Van C. G. A novel TECTA mutation confirms the recognizable phenotype among autosomal recessive hearing impairment families. *Int. J. Pediatr. Otorhinolaryngol.* **72**: 249-255 (2008).